

Gries & Associates, LLC

Certified Public Accountants 501 S. Cherry Street Ste 1100 Denver, Colorado 80246

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders Healthmed Services. Ltd.

Report on the Financial Statements

We have audited the accompanying balance sheets of Healthmed Services, Ltd. (the Company), which comprise the balance sheet as of December 31, 2021 and 2020, respectively, and the related statements of Operations, Changes in Stockholder's Equity, and Cash Flows for the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatements.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Emphasis of Matter Regarding Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As described in Note 3 to the financial statements, the Company has not generated any revenues since inception and sustained a net loss of \$168,396 for the year under audit and has accumulated losses of \$800,709. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our opinion is not modified with respect to this matter.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Healthmed Services, Ltd. as of December 31, 2021 and 2020, respectively, and the results of its operations and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Emphasis of Matters-Risks and Uncertainties

The Company is not able to predict the ultimate impact that COVID -19 will have on its business. However, if the current economic conditions continue, the pandemic could have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company plans to operate.





Certified Public Accountants 501 S. Cherry Street Ste 1100 Denver, Colorado 80246

Dies & Assortes, LLC

We have served as the Company's auditor since 2021.

Denver, Colorado February 3, 2022

HEALTHMED SERVICES, LTD. Balance Sheets (Audited)

ASSETS	December 31, 2021		December 31, 2020	
Current assets				
Cash		-		
Total current assets		-		-
Total assets	\$	-	\$	
LIABILITIES AND STOCKHOLDERS' DEFICIT				
Current liabilities				
Accounts payable and accrued liabilities		2,952		-
Due to related party		32,694		
Total current liabilities		35,646		-
Total liabilities		35,646		
Stockholders' deficit				
Preferred stock, par value \$.001; 75,000,000 shares authorized;				
5,000,000 and 50,000,000 issued and outstanding as of				
December 31, 2021 and 2020, respectively.		50,000		50,000
Common stock; \$0.0001 par value; ,1,000,000,000 shares authorized;				
627,313,003 and 627,313,003 shares issued and outstanding as of				
December 31, 2021 and 2020, respectively.		627,313		627,313
Additional paid-in capital		87,750		-
Accumulated deficit		(800,709)		(677,313)
Total stockholders' deficit		(35,646)		-
Total liabilities and stockholders' deficit	\$	-	\$	_

HEALTHMED SERVICES, LTD. STATEMENT OF OPERATIONS

(Audited)

	For the years ended				
	December 31, 2021		cember 31, 2020		
Revenue		-	-		
Operating expenses					
General and administrative	35,0	646	-		
Total operating expenses	35,0	646	-		
Loss from operations	(35,	646)	-		
Other expenses					
Loss on asset purchase agreement	(132,	750)			
Total other expenses	(132,	750)	-		
Net Income	\$ (168,	396) \$	_		
Net loss per common share: basic and diluted	\$ (0	0.00) \$			
Basic weighted average common shares outstanding	627,313,0	003	627,313,003		

HEALTHMED SERVICES, LTD. STATEMENTS OF STOCKHOLDERS' DEFICIT (Audited)

	Preferred Stock Con		Common St	tock	Additional	Accumulated	Total Stockholders'	
	Shares	Amount	Shares	Amount	Paid-in Capital	Deficit	Deficit	
Balance, December 31, 2019	50,000,000	50,000	627,313,003	627,313	-	(677,313)	-	
Net loss		-		-	-	-	-	
Balance, December 31, 2020	50,000,000	50,000	627,313,003	627,313	-	(677,313)	-	
Return and cancellation of Preferred shares	(45,000,000)	(45,000)	-	-	-	45,000	-	
Issuance of Preferred shares for assets purchase	45,000,000	45,000	-	-	87,750	-	132,750	
Net loss	-	-	-	-		(168,396)	(168,396)	
Balance, December 31, 2021	50,000,000	50,000	627,313,003	627,313	87,750	(800,709)	(35,646)	

HEALTHMED SERVICES, LTD. STATEMENTS OF CASH FLOWS (Audited)

	For the years ended			
	December 31, 2021		December 31, 2020	
Cash Flows from Operating Activities				
Net Income	\$	(168,396)	\$	-
Adjustments to reconcile net loss to net cash provided by operating ac	ctivities:			
Loss on asset purchase		132,750		
Changes in assets and liabilities				
Increase in accounts payable		2,952		-
Net cash used in operating activities		(32,694)		-
Cash Flows from Financing Activities				
Proceeds from related party debt		32,694		-
Net cash from financing activities		32,694		-
Net increase (decrease) in cash				
Cash, beginning of period		-		-
Cash, end of period	\$	-	\$	-
Non-Cash investing and financing transactions				
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION	ON:			
Non-cash investing and financing activities:				
Return and cancellation of Preferred stock		45,000		-

HEALTHMED SERVICES, LTD.

NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 2021 and 2020 (Audited)

NOTE 1 – NATURE AND DESCRIPTION OF BUSINESS

HealthMed Services, Ltd. the ("the Company") was incorporated in the State of Nevada on September 14, 2000 as Telemax Communications, Inc. On July 14, 2003, the Company changed its name to HealthMed Services, Ltd. TheCompany has no operations and in accordance with Accounting Standards Codification (ASC) Topic 915 is considered to be in the development stage.

On April 16, 2021, A board member agreed to sell, assign, and transfer 4,850,000 shares of Company's Series A Preferred Stock and deliver to the Company for cancellation and return to treasury 45,000,000 shares of Company Series A Preferred Stock.

On April 27, 2021, James Shipley resigned as President, Secretary, Treasurer, and Director of the Company at which time Rasmus Refer was appointed to these positions.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The Company's financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").

The financial statements have been prepared in accordance with accounting principles generally accepted in The United States of America and the rules and regulations of the OTC Markets alternative reporting standard for interim financial information. Accordingly, they do not include all the information necessary for a comprehensive presentation of financial position and results of operations.

It is management's opinion, however, that all material adjustments (consisting of normal and recurring adjustments) have been made which are necessary for a fair financial statements presentation. The results for the interim period are not necessarily indicative of the results to be expected for the year.

Use of estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates.

Cash and cash equivalents

For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. The carrying value of these investments approximates fair value. The Company did not have any cash equivalents as of December 31, 2021 and 2020.

Stock-based compensation

The Company follows ASC 718-10, "Stock Compensation", which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 is a revision to SFAS No. 123, "Accounting for Stock-Based Compensation," and supersedes Accounting Principles Board ("APB") Opinion No. 25, "Accounting for Stock Issued to Employees," and its related implementation guidance. ASC 718-10 requires measurement of the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.

HEALTHMED SERVICES, LTD.

NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 2021 and 2020 (Audited)

Income Taxes

The Company's calculation of its tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in various taxing jurisdictions. The Company recognizes tax liabilities for uncertain tax positions based on management's estimate of whether it is more likely than not that additional taxes will be required. The Company had no uncertain tax positions as of December 31, 2021 and 2020.

Deferred income taxes are recognized in the consolidated financial statements for the tax consequences in future years of differences between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates. Temporary differences arise from net operating losses, differences in depreciation methods of archived images, and property and equipment, stock-based and other compensation, and other accrued expenses. A valuation allowance is established when it is determined that it is more likely than not that some or all of the deferred tax assets will not be realized.

The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the actual liability for U.S., or the various state jurisdictions, may be materially different from management's estimates, which could result in the need to record additional tax liabilities or potentially reverse previously recorded tax liabilities. Interest and penalties are included in tax expense.

The Company includes interest and penalties arising from the underpayment of income taxes in the statements of operation in the provision for income taxes. As of December 31, 2021 and 2020, the Company had no accrued interest or penalties related to uncertain tax positions.

Earnings per share

The Company follows ASC Topic 260 to account for the earnings per share. Basic earnings per common share ("EPS") calculations are determined by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.

Revenue recognition

We recognize revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Board's ("FASB") Accounting Standards Codification ("ASC") 606, Revenue From Contracts with Customers, which requires that five basic criteria be met before revenue can be recognized: (i) identify the contract with the customer; (ii) identity the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation.

Revenue recognition occurs at the time product is shipped to customers, when control transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. We only record revenue when collectability is probable.

Fair value of financial instruments

The Company measures fair value in accordance with ASC 820 - Fair Value Measurements. ASC 820 defines fair value and establishes a three-level valuation hierarchy for disclosures of fair value measurements. ASC 820 establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by ASC 820 are:

- Level 1 Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.
- Level 2 Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument's anticipated life.
- Level 3 Inputs reflect management's best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the

HEALTHMED SERVICES, LTD. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 2021 and 2020

(Audited)

model. Valuation of instruments includes unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

As defined by ASC 820, the fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale, which was further clarified as the price that would be received to sell an asset or paid to transfer a liability ("an exit price") in an orderly transaction between market participants at the measurement date.

The reported fair values for financial instruments that use Level 2 and Level 3 inputs to determine fair value are based on a variety of factors and assumptions. Accordingly, certain fair values may not represent actual values of the Company's financial instruments that could have been realized as of December 31, 2021 or that will be recognized in the future, and do not include expenses that could be incurred in an actual settlement. The carrying amounts of the Company's financial assets and liabilities, such as cash, accounts receivable, receivables from related parties, prepaid expenses and other, accounts payable, accrued liabilities, and related party and third-party notes payables approximate fair value due to their relatively short maturities. The Company's notes payable to related parties approximates the fair value of such instrument based upon management's best estimate of terms that would be available to the Company for similar financial arrangements at December 31, 2021 and 2020.

Recent accounting pronouncements

Company management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

NOTE 3 - GOING CONCERN

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.

Management evaluated all relevant conditions and events that are reasonably known or reasonably knowable, in the aggregate, as of the date the consolidated financial statements are issued and determined that substantial doubt exists about the Company's ability to continue as a going concern. The Company's ability to continue as a going concern is dependent on the Company's ability to generate revenues and raise capital. The Company has not generated any revenues to provide sufficient cash flows to enable the Company to finance its operations internally. As of December 31, 2021, the Company had \$0 cash on hand. At December 31, 2021 the Company has an accumulated deficit of \$800,709. For the year ended December 31, 2021, the Company had a net loss of \$168,396, and cash used in operations of \$32,694. These factors raise substantial doubt about the Company's ability to continue as a going concern within one year from the date of filing.

Over the next twelve months management plans to raise additional capital and to invest its working capital resources in sales and marketing in order to increase the distribution and demand for its products. However, there is no guarantee the Company will generate sufficient revenues or raise capital to continue operations. If the Company fails to generate sufficient revenue and obtain additional capital to continue at its expected level of operations, the Company may be forced to scale back or discontinue its sales and marketing efforts. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

HEALTHMED SERVICES, LTD.

NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 2021 and 2020 (Audited)

NOTE 4 – RELATED PARTY TRANSACTIONS

During the year ended December 31, 2021, the Company borrowed \$32,694 from a shareholder for payment of operating expenses. The advances have 0% interest and are due upon demand. As of December 31, 2021 and 2020, the Company had amounts due to related party of \$32,694 and \$0 respectively.

Assets purchase agreement

On September 14, 2021, the Company issued 45,000,000 shares of the Company's Series A Preferred stock valued at \$132,750 to its majority shareholder for certain intangible assets. The acquisition of the intangible assets was determined to be a common control transaction. As a result, the assets and liabilities assumed were recorded on the Company's financial statements at their respective carry-over basis of \$0 and as such the Company recorded a loss on the asset purchase of \$132,750

NOTE 5 – INCOME TAXES

For the years ended December 31, 2021 and 2020, the cumulative net operating loss carry-forward from continuing operations is approximately \$800,709 and \$677,313, respectively, and will expire beginning in the year 2031.

The cumulative tax effect at the expected rate of 21% of significant items comprising our net deferred tax amount is as follows as of December 31, 2021 and 2020:

	2021	2020	
Deferred tax asset attributable to:			
Net operating loss carryover	\$ 168,149	\$	142,236
Valuation allowance	 (168,149)		(142,236)
Net deferred tax asset	\$ 	\$	

Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards of approximately \$800,709 for Federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited as to use in future years.

Due to the enactment of the Tax Reform Act of 2017, the corporate tax rate for those tax years beginning with 2018 has been reduced to 21%.

NOTE 6 – STOCKHOLDERS' DEFICIT

The Company is authorized to issue 1,000,000,000 authorized shares of common stock with a par value of \$0.001. The Company had 627,313,003 and 627,313,003 issued and outstanding shares of common stock as of December 31, 2021 and 2020, respectively.

The Company also has 75,000,000 authorized shares of preferred stock with a par value of \$0.001 of which the Company has designated 50,000,000 shares as Series A Preferred Stock. Each share of Series A Preferred Stock is convertible, at any time, at the option of the holder at a rate of 30% of the market price of the stock based on a 10 day average trading price of the common stock. In addition the holders of the Series A Preferred have voting rights equal to 20 votes for each Preferred share held. As of December 31, 2021 and 2020, 50,000,000 and 50,000,000 shares of Series A Preferred stock issued and outstanding, respectively.

The Company has also designated 7,500,000 Series B Preferred shares, and 15,000,000 Series C Preferred shares. No shares of Series B Preferred stock or Series C Preferred Stock are issued and outstanding.

On April 21, 2021, the shareholder of 50,000,000 shares of the Company's Preferred stock returned and returned to Treasury 45,000,000 shares to the Company's Series A preferred shares.

HEALTHMED SERVICES, LTD. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 2021 and 2020 (Audited)

On September 14, 2021, the Company issued to 45,000,000 shares of the Company's Series A Preferred stock to its majority shareholder for certain intangible assets (See Note 4).

On August 24, 2021, the Company's board approved a name change and one for two thousand [1/2,000] reverse stock split with an effective date determined by the approval of FINRA. As of the date of filing the Company has not received approval from FINRA.

NOTE 7 – SUBSEQUENT EVENTS

In accordance with ASC Topic 855-10, the Company has analyzed its operations subsequent to December 31, 2021 to the date these financial statements were available to be issued and has determined that it does not have any material subsequent events to disclose in these financial statements.